- One year from the March 2020 lows, this article takes a look back at the worst-performing stocks amidst the strong market recovery.
- Interestingly, six biopharma companies were the laggards, even as the industry delivered innovative and rapid solutions to combat the global public health crisis.
- This article also contains a broader list of the worst decile of stocks over this period - a combination of companies with idiosyncratic issues and lagging defensive names.
For further details see:
The 6 Worst S&P 500 Stocks Since COVID Lows Share An Unexpected Sector